Daily Ards Research Analysis
Across ARDS-relevant research, a multinational cohort mapped pandemic-era antimicrobial use shifts, a Swedish multicentre study linked blood group O to higher ARDS risk but lower ARDS mortality, and a dual-case report showed successful VV-ECMO rescue in fulminant CA-MRSA pneumonia. These findings span stewardship policy, host susceptibility, and rescue therapy.
Summary
Across ARDS-relevant research, a multinational cohort mapped pandemic-era antimicrobial use shifts, a Swedish multicentre study linked blood group O to higher ARDS risk but lower ARDS mortality, and a dual-case report showed successful VV-ECMO rescue in fulminant CA-MRSA pneumonia. These findings span stewardship policy, host susceptibility, and rescue therapy.
Research Themes
- Pandemic-era antimicrobial stewardship in critical care
- Host factors influencing ARDS susceptibility and outcomes
- Rescue strategies (VV-ECMO) for severe pneumonia progressing to ARDS
Selected Articles
1. The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort study.
Using patient-level data from nine countries, antimicrobial consumption in ICU and COVID-19 wards for pneumonia/ARDS/sepsis increased heterogeneously during COVID-19. Interrupted time-series linked policy (WHO guidance) to azithromycin de-implementation and variant emergence (Delta) to surges in carbapenems/fluoroquinolones in specific settings, underscoring stewardship needs.
Impact: Provides multinational, patient-level evidence with ITS that connects policy and variant dynamics to real-world antimicrobial use in ARDS-relevant populations, informing stewardship and preparedness.
Clinical Implications: Health systems should monitor DOT/PDD, curtail routine macrolide use after guideline updates, and guard against carbapenem overuse; pandemic waves warrant anticipatory stewardship interventions in ICU pneumonia/ARDS/sepsis cohorts.
Key Findings
- Meropenem prescriptions increased in Bangladesh (with higher PDD) and Turkey during the pandemic.
- Moxifloxacin use increased in Bangladesh with higher DOT; piperacillin/tazobactam increased in Italy with higher DOT and PDD.
- Azithromycin use rose in Bangladesh and Brazil, but ITS showed significant post-WHO-guideline decreases in India and South Korea.
- Following Delta variant emergence, meropenem and moxifloxacin increased in Bangladesh and TMP-SMX increased in India.
Methodological Strengths
- Multinational patient-level dataset across nine countries
- Interrupted time-series analyses linking temporal policy/variant events to usage
- Use of DOT and PDD alongside regression-based comparisons
Limitations
- Retrospective observational design with potential unmeasured confounding
- Heterogeneity in care settings and guideline adoption across countries
- No direct linkage to resistance emergence or patient-centered outcomes
Future Directions: Prospective, multicountry stewardship interventions linking antimicrobial use, resistance trends, and patient outcomes in ICU pneumonia/ARDS/sepsis, with evaluation of policy timing effects.
BACKGROUND: This study aimed to evaluate the trends in antimicrobial prescription during the first 1.5 years of COVID-19 pandemic. METHODS: This was an observational, retrospective cohort study using patient-level data from Bangladesh, Brazil, India, Italy, Malawi, Nigeria, South Korea, Switzerland and Turkey from patients with pneumonia and/or acute respiratory distress syndrome and/or sepsis, regardless of COVID-19 positivity, who were admitted to critical care units or COVID-19 specialized wards. The changes of antimicrobial prescription between pre-pandemic and pandemic were estimated using logistic or linear regression. Pandemic effects on month-wise antimicrobial usage were evaluated using interrupted time series analyses (ITSAs). RESULTS: Antimicrobials for which prescriptions significantly increased during the pandemic were as follows: meropenem in Bangladesh (95% CI: 1.94-4.07) with increased prescribed daily dose (PDD) (95% CI: 1.17-1.58) and Turkey (95% CI: 1.09-1.58), moxifloxacin in Bangladesh (95% CI: 4.11-11.87) with increased days of therapy (DOT) (95% CI: 1.14-2.56), piperacillin/tazobactam in Italy (95% CI: 1.07-1.48) with increased DOT (95% CI: 1.01-1.25) and PDD (95% CI: 1.05-1.21) and azithromycin in Bangladesh (95% CI: 3.36-21.77) and Brazil (95% CI: 2.33-8.42). ITSA showed a significant drop in azithromycin usage in India (95% CI: -8.38 to -3.49 g/100 patients) and South Korea (95% CI: -2.83 to -1.89 g/100 patients) after WHO guidelines v1 release and increased meropenem usage (95% CI: 93.40-126.48 g/100 patients) and moxifloxacin (95% CI: 5.40-13.98 g/100 patients) in Bangladesh and sulfamethoxazole/trimethoprim in India (95% CI: 0.92-9.32 g/100 patients) following the Delta variant emergence. CONCLUSIONS: This study reinforces the importance of developing antimicrobial stewardship in the clinical settings during inter-pandemic periods.
2. Blood group O is associated with ARDS development but exhibits lower mortality in the intensive care unit - A retrospective multicentre study.
In 1,439 ICU patients, 10% had ARDS. Compared with blood group A, blood group O had higher odds of having/developing ARDS (OR 1.79, 95% CI 1.13–2.84) but lower mortality once ARDS occurred, suggesting ABO-related susceptibility and outcome differences.
Impact: Identifies a host factor (ABO blood group) linked to ARDS susceptibility and outcomes, countering prior emphasis on blood group A and motivating mechanistic studies.
Clinical Implications: ABO type may be considered in ARDS risk stratification models and subgroup analyses in trials; findings are not practice-changing yet and require external validation.
Key Findings
- Among 1,439 ICU patients, 10% met the Berlin definition for ARDS.
- Blood group O was associated with increased odds of having/developing ARDS versus blood group A (OR 1.79, 95% CI 1.13–2.84).
- Mortality among ARDS patients was lower in blood group O compared with blood group A.
Methodological Strengths
- Use of Berlin definition for ARDS and radiologist review of chest radiographs
- Multivariable logistic regression controlling for confounders
- Multicentre ICU cohort
Limitations
- Retrospective single-region cohort from two ICUs in Sweden (2016)
- Potential residual confounding and limited generalizability
- Exact effect sizes for mortality reduction not detailed in abstract
Future Directions: Validate findings across diverse populations and explore mechanisms (e.g., vWF, thrombosis, endothelial biology) linking ABO to ARDS susceptibility and outcomes.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in the intensive care unit (ICU). Previous studies have suggested that blood group A increases the risk of developing ARDS following sepsis and major trauma. This study investigated the association between ABO and Rh blood groups and ARDS development and mortality in ARDS. METHODS: Patients admitted to the ICUs at Skåne University Hospital in Lund and Malmö, Sweden, in 2016 were retrospectively screened for ARDS according to the Berlin definition. Clinical data, patient characteristics, lab results, and survival data were collected from medical records and registry data. In addition, chest radiographs were reviewed by radiologists. ARDS development and 30-day mortality were analysed using multivariable logistic regression. RESULTS: A total of 1439 ICU patients were included. Of these, 10% had ARDS. Blood group O was associated with an increased risk of having or developing ARDS compared to blood group A (odds ratio [OR] 1.79, 95% confidence interval [CI] 1.13-2.84, CONCLUSION: In this study of ICU patients, blood group O was associated with an increased risk of having or developing ARDS but a decreased mortality in ARDS compared to blood group A. Further studies are needed to clarify the relationship and underlying mechanisms of the ABO blood group and ARDS.
3. Severe pneumonia combined with septic shock caused by community-acquired methicillin-resistant Staphylococcus aureus treated with veno-venous ECMO: A case report.
Two female patients with fulminant CA-MRSA pneumonia rapidly developed ARDS and septic shock refractory to conventional ventilation. Early VV-ECMO plus targeted antibiotics (including linezolid) led to recovery and successful weaning from ECMO and ventilation, highlighting the role of rescue ECMO.
Impact: Provides detailed clinical course demonstrating feasibility and potential benefit of early VV-ECMO with appropriate anti-MRSA therapy in fulminant community-acquired pneumonia progressing to ARDS and shock.
Clinical Implications: In severe CA-MRSA pneumonia with refractory hypoxemia and shock, early VV-ECMO alongside MRSA-active therapy (e.g., linezolid) should be considered within a multidisciplinary framework.
Key Findings
- Two female patients (14 and 32 years) with CA-MRSA pneumonia rapidly progressed to ARDS and septic shock.
- Conventional mechanical ventilation failed to maintain oxygenation; VV-ECMO was initiated.
- With targeted antibiotics including linezolid, both patients improved, were weaned from ECMO and ventilation, and were discharged.
Methodological Strengths
- Microbiological confirmation of CA-MRSA
- Detailed clinical timelines of VV-ECMO initiation and weaning
Limitations
- Small case report without controls, limiting generalizability
- Cannot infer comparative effectiveness or optimal timing of ECMO
Future Directions: Prospective registries or multicentre cohorts to define timing, patient selection, and antibiotic strategies for VV-ECMO in CA-MRSA pneumonia with ARDS.
RATIONALE: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) pneumonia is a severe and rapidly progressing infection that can lead to acute respiratory distress syndrome and septic shock. The use of venovenous extracorporeal membrane oxygenation (ECMO) may improve outcomes in critically ill patients who fail conventional mechanical ventilation. PATIENT CONCERNS: Two female patients, aged 14 and 32 years, presented with fever and cough before hospital admission. Both patients rapidly developed severe respiratory distress and hemodynamic instability, raising concerns for a life-threatening infection. DIAGNOSES: Both patients were diagnosed with severe pneumonia caused by CA-MRSA, complicated by acute respiratory distress syndrome and septic shock. Microbiological testing confirmed the presence of CA-MRSA in respiratory samples. INTERVENTIONS: The patients were initially treated with broad-spectrum anti-infective agents, including linezolid, targeting CA-MRSA. Due to the failure of conventional mechanical ventilation to maintain adequate oxygenation, venovenous ECMO was initiated to support respiratory function. The patients also received hemodynamic support and other adjunctive therapies for septic shock. OUTCOMES: Following the initiation of ECMO and targeted antibiotic therapy, both patients showed significant clinical improvement. Lung function recovered well, and they were successfully weaned off ECMO and mechanical ventilation. Both patients were eventually discharged with favorable outcomes. LESSONS: CA-MRSA pneumonia can progress rapidly to severe respiratory failure and septic shock, necessitating aggressive interventions. Venovenous ECMO, combined with timely and appropriate antibiotic therapy can be life-saving in such cases. This report highlights the importance of early recognition, multidisciplinary management, and the potential benefits of ECMO in severe CA-MRSA pneumonia. It serves as a clinical reference for the treatment of similar cases.